Ensemble Discovery Completes $15 Million Financing
Robert Buderi11/12/07
Cambridge-based Ensemble Discovery, which is developing therapeutics and bioassays using its proprietary “DNA-programmed chemistry” platform, has completed a $15 million Series B funding round, PE Week reported. The three-year-old company received a first tranche payment of $10 million back in January, with the remainder just announced. Participants in the round included Aeneas Venture (Harvard Management Company), ARCH Venture Partners, Boston University Technology Development Fund, CMEA Ventures, Flagship Ventures, Harris & Harris Group, and Oxford Bioscience Partners.
Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.
